Provider notes

• NMUH:
• No restriction stated
• RFL:
• HIV medicine only
• RNOH:
• Non-formulary  
• UCLH:
• WH:
• Non-formulary

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • HIV medicine only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Approved for HIV in line with NHSE Commissioning Policy 200210P.

Provider notes

• NMUH:
  
  • Restricted to HIV team ONLY
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
• To be used in accordance with the London HIV consortium BHIVA guidelines
• For HIV team only
• Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
• RFL:
• HIV medicine only
• RNOH:
• Non-formulary  
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• No restriction stated
• RFL:
• HIV medicine only
• RNOH:
• Non-formulary  
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• No restriction stated
• RFL:
• HIV medicine only
• RNOH:
• Restricted for use in accordance with RNOH Sharps Policy and Inoculation Management (see policy)
• UCLH:
• WH:
• For TB / HIV clinic and post-exposure prophylaxis